Medical devices, healthcare technology and the business of care
PMA approval · P970051

NUCLEUS 24 COCHLEAR IMPLANT SYSTEM

Cochlear Americas · Decision date Jun 25, 1998

MEDTECHLEDGER EXPLANATIONP970051

What did the FDA approve?

FDA approved PMA P970051 for the Nucleus 24 Cochlear Implant System on June 25, 1998. The approval statement describes the device as intended to restore a level of auditory sensation to adults and children via electrical stimulation of the auditory nerve. The applicant was Cochlear Americas, and the device is classified under product code MCM as an implant, cochlear.

This record is an original PMA approval, not a supplement or manufacturing notice. The source does not include a supplement type or supplement reason. The statement reports the device's intended purpose only; it does not provide independent evidence of safety or clinical effectiveness, and no specific technical modifications, indications, or trial data are described in the supplied fields.

FDA approval order statement

INTENDED TO RESTORE A LEVEL OF AUDITORY SENSATIONTO ADULTS AND CHILDREN VIA ELECTRICAL STIMULATION OF THE AUDITORY NERVE.
Regulatory pathway
Original PMA
Clinical specialty
Ear, Nose, Throat
Decision date
Jun 25, 1998

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P970051
Regulatory pathway
Premarket approval application
Product code
MCM
Decision code
APPR
Decision date
Jun 25, 1998
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implant, cochlear.

Product code
MCM
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P970051 received

    Application receipt date recorded by FDA.

  2. P970051 · FDA decision

    APPR

  3. P970051/S244 · Related supplement

    Nucleus 24 Cochlear Implant System

Timeline entries are records held by MedtechLedger for P970051. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P970051

Product / regulatory recordCompanyPathwayDecision dateSource
Cochlear AmericasPMA supplementSep 28, 2026FDA

Explore the linked device profile

Other records with product code MCM

Product / regulatory recordCompanyPathwayDecision dateSource
Med-El Corp.PMA supplementOct 9, 2026FDA
Cochlear AmericasPMA supplementSep 28, 2026FDA
Cochlear AmericasPMA supplementSep 28, 2026FDA
Advanced BionicsPMA supplementSep 18, 2026FDA
Advanced BionicsPMA supplementSep 4, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Cochlear Americas

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
10350 Park Meadows Dr., Lone Tree, CO, 80124

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records